Explore the vast range of titles available.

People with brain injury can have lower resiliency compared to the general public. Yet, resiliency facilitates positive processes to negotiate adversity after brain injury. Therefore, measuring resiliency after a brain injury is important. The review aimed to (1) identify self-report resiliency outcome measures for use with people after acquired brain injury, using the process-based Traumatic Brain Injury Resiliency Model as the guiding conceptual framework, and (2) summarize the psychometric properties of the identified outcome measures and the utility of these measures in clinical rehabilitation. The COSMIN guidelines for systematic reviews were followed to ensure appropriate reporting for each measure. Databases CINAHL, EMBASE, Medline, and PsychINFO were searched and independently reviewed by two people. Articles providing data on psychometric properties for measures of resilience for people with brain injury were retrieved. Psychometric properties and clinical utility (number of items, scoring details) were summarized. Thirty-two articles were retrieved, including nine measures of resiliency: Acceptance and Action Questionnaire-Acquired Brain Injury, Confidence after Stroke Measure, Connor-Davidson Resilience Scale, Daily Living Self-Efficacy Scale, General Self-Efficacy Scale, Participation Strategies Self-Efficacy Scale, Resilience Scale, Robson Self-Esteem Scale, and the Stroke Self-Efficacy Questionnaire. All measures have acceptable to excellent psychometric properties in accordance with the COSMIN guidelines. There are established measures of resiliency in brain injury rehabilitation. Future work may explore use of these measures in a clinical context and implementation of rehabilitation goals for improving resiliency after brain injury.

Needs of parents with children with scoliosis are complex and depend on their child’s treatments. The purpose of this study was to identify needs of parents with children with scoliosis. This qualitative description involved interviews with parents of children at various stages of treatment. A convenience, then purposeful sample of 16 parents (12 mothers, two fathers, and two stepfathers) was interviewed; interviews were transcribed and analyzed using thematic analysis. Parents’ needs included: Needing reliable medical information; Desiring information on complementary treatments; Wanting help in supporting and advocating for their child; Needing to protect the child and family; and Seeking connection and support. Although many parents’ needs are being met, this study recommends a nursing role aimed at providing parents with reliable medical information, discussing alternative treatments, assisting parents in their role of supporting their child, helping parents in their advocacy efforts, and referring parents to appropriate connections.

People with brain injury can have lower resiliency compared to the general public. Yet, resiliency facilitates positive processes to negotiate adversity after brain injury. Therefore, measuring resiliency after a brain injury is important. The review aimed to (1) identify self-report resiliency outcome measures for use with people after acquired brain injury, using the process-based Traumatic Brain Injury Resiliency Model as the guiding conceptual framework, and (2) summarize the psychometric properties of the identified outcome measures and the utility of these measures in clinical rehabilitation. The COSMIN guidelines for systematic reviews were followed to ensure appropriate reporting for each measure. Databases CINAHL, EMBASE, Medline, and PsychINFO were searched and independently reviewed by two people. Articles providing data on psychometric properties for measures of resilience for people with brain injury were retrieved. Psychometric properties and clinical utility (number of items, scoring details) were summarized. Thirty-two articles were retrieved, including nine measures of resiliency: Acceptance and Action Questionnaire-Acquired Brain Injury, Confidence after Stroke Measure, Connor-Davidson Resilience Scale, Daily Living Self-Efficacy Scale, General Self-Efficacy Scale, Participation Strategies Self-Efficacy Scale, Resilience Scale, Robson Self-Esteem Scale, and the Stroke Self-Efficacy Questionnaire. All measures have acceptable to excellent psychometric properties in accordance with the COSMIN guidelines. There are established measures of resiliency in brain injury rehabilitation. Future work may explore use of these measures in a clinical context and implementation of rehabilitation goals for improving resiliency after brain injury.

People with brain injury can have lower resiliency compared to the general public. Yet, resiliency facilitates positive processes to negotiate adversity after brain injury. Therefore, measuring resiliency after a brain injury is important. The review aimed to (1) identify self-report resiliency outcome measures for use with people after acquired brain injury, using the process-based Traumatic Brain Injury Resiliency Model as the guiding conceptual framework, and (2) summarize the psychometric properties of the identified outcome measures and the utility of these measures in clinical rehabilitation. The COSMIN guidelines for systematic reviews were followed to ensure appropriate reporting for each measure. Databases CINAHL, EMBASE, Medline, and PsychINFO were searched and independently reviewed by two people. Articles providing data on psychometric properties for measures of resilience for people with brain injury were retrieved. Psychometric properties and clinical utility (number of items, scoring details) were summarized. Thirty-two articles were retrieved, including nine measures of resiliency: Acceptance and Action Questionnaire-Acquired Brain Injury, Confidence after Stroke Measure, Connor-Davidson Resilience Scale, Daily Living Self-Efficacy Scale, General Self-Efficacy Scale, Participation Strategies Self-Efficacy Scale, Resilience Scale, Robson Self-Esteem Scale, and the Stroke Self-Efficacy Questionnaire. All measures have acceptable to excellent psychometric properties in accordance with the COSMIN guidelines. There are established measures of resiliency in brain injury rehabilitation. Future work may explore use of these measures in a clinical context and implementation of rehabilitation goals for improving resiliency after brain injury.

In Science—The Endless Frontier, Vannevar Bush wrote that reaping the potential benefits of science conducted at federal laboratories requires the discoveries made in the laboratories be transferred to society. In federal laboratories, Offices of Research and Technology Applications (ORTAs) are tasked with transferring laboratory-developed technologies to the market, allowing society to reap the benefits provided by scientific investments. In fiscal year 2016, the Technology Partnerships Office of the National Institute of Standards and Technology (NIST) conducted a first-of-its-kind survey of the ORTAs of more than 50 federal laboratories to obtain information on their organization and operation. We present descriptive analyses of the responses to this survey in two topical areas: organizational characteristics and technology transfer characteristics. We disaggregated the data across the dimension of budget size to describe similarities and differences in responses across the budget categories. Among the relationships we observed, we found that ORTAs with larger technology transfer budgets report higher frequencies of conducting internal technology transfer activities, such as patent prosecution (e.g., drafting patents, filing patent applications, and responding to actions from the patent office) and market analysis. Additionally, we provide context to the data by summarizing the relevant research on ORTAs at universities, and we present potential inferences that may be drawn from that body of research and applied to the data on ORTAs at federal laboratories.

Tyrosine kinase is a key enzyme activity utilized in many intracellular messaging pathways. Understanding the role of particular tyrosine kinases in malignancies has allowed for the design of tyrosine kinase inhibitors (TKIs), which can target these enzymes and interfere with downstream signaling. TKIs have proven to be successful in the treatment of chronic myeloid leukemia, renal cell carcinoma and gastrointestinal stromal tumor, and other malignancies. Scattered reports have suggested that these agents appear to affect blood glucose (BG). We retrospectively studied the BG concentrations in diabetic (17) and nondiabetic (61) patients treated with dasatinib (8), imatinib (39), sorafenib (23), and sunitinib (30) in our clinical practice. Mean declines of BG were dasatinib (53 mg/dL), imatinib (9 mg/dL), sorafenib (12 mg/dL), and sunitinib (14 mg/dL). All these declines in BG were statistically significant. Of note, 47% (8/17) of the patients with diabetes were able to discontinue their medications, including insulin in some patients. Only one diabetic patient developed symptomatic hypoglycemia while on sunitinib. The mechanism for the hypoglycemic effect of these drugs is unclear, but of the four agents tested, c-kit and PDGFRβ are the common target kinases. Clinicians should keep the potential hypoglycemic effects of these agents in mind; modification of hypoglycemic agents may be required in diabetic patients. These results also suggest that inhibition of a tyrosine kinase, be it c-kit, PDGFRβ or some other undefined target, may improve diabetes mellitus BG control and it deserves further study as a potential novel therapeutic option.